YCBD Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Not a good buy right now. The stock just surged ~35% in the regular session to $1.03, but the broader trend remains bearish (SMA200 > SMA20 > SMA5) and momentum is not confirming a sustainable breakout (MACD histogram still below 0). With no Intellectia buy signals today and a probabilistic pattern forecast skewing negative over the next week, the risk/reward for an impatient buyer is unfavorable at current levels. If already holding, this is a reasonable spot to trim/exit into strength rather than initiate a new position.
Price/Trend: Sharp one-day spike (close $1.03 vs prior $0.771, +34.89%) within a still-bearish moving average stack (SMA200 > SMA20 > SMA5), implying the longer-term downtrend is intact and today may be a counter-trend pop. Momentum: MACD histogram -0.0114 (below zero) and only contracting negatively—bearish momentum is easing but not reversed. RSI(6) ~68.6 (upper-neutral/near-overbought), suggesting limited immediate upside without consolidation. Levels: Pivot 0.957 is the key near-term line; holding above it keeps the bounce alive. Resistance at R1 1.185 then R2 1.325. Supports: S1 0.73 then S2 0.59. Pattern/Return bias: Similar-pattern stats indicate ~80% chance of -0.23% next day and -4.39% next week, with +5.69% next month—near-term pullback risk dominates.
Intellectia Proprietary Trading Signals:
Positioning/Flows: Hedge funds neutral (no notable trend last quarter). Insiders neutral (no notable trend last month). Congress trading: no recent congress trading data available.
News-driven catalyst (2026-01-29): Acquisition of Bluebird Botanicals and leveraging Bluebird’s self-affirmed GRAS determination could improve regulatory/compliance positioning and management expects ~10% revenue growth contribution.
Operational catalyst: Launch of a GRAS/regulatory science program may lower compliance costs over time by reducing reliance on external consultants.
Upcoming catalyst: Earnings on 2026-02-12 (After Hours) could re-rate the stock if revenue acceleration and margin gains persist.
Post-surge technical risk: Large single-day move with bearish longer-term trend increases probability of mean reversion/pullback.
Earnings risk: With small-cap microcap dynamics (market cap shown as ~$12.90M), earnings can cause outsized downside if growth/margins disappoint.
Profitability remains weak: Net losses and EPS deterioration reduce confidence that revenue gains translate into shareholder value near-term.
No options tape: Lack of options data limits sentiment confirmation from derivatives markets.
Latest quarter: 2025/Q4. Revenue $4.72M (+3.61% YoY), indicating modest top-line growth. Gross margin improved to 53.28% (+12.07% YoY), a clear positive operational trend. However, net income fell to -$0.68M (down -41.14% YoY) and EPS dropped to -0.08 (down -94.33% YoY), showing profitability and per-share results worsened despite better gross margins—suggesting operating costs/other expenses are still a major headwind.
No analyst rating/price target change data was provided, so a formal Wall Street trend summary cannot be confirmed. Pros view (what bulls would cite): Bluebird acquisition + GRAS/regulatory focus could improve compliance credibility and support distribution/healthcare channel positioning; gross margin improved meaningfully in the latest quarter. Cons view (what bears would cite): Revenue growth is still modest, losses persist and EPS deterioration is severe; the chart remains structurally bearish despite today’s pop; microcap liquidity/event risk is high. Influential buying/selling: No recent congress trading data available; insiders and hedge funds show neutral recent activity based on provided trends.
